| INTRODUCTION
Liver cirrhosis is a significant cause of global health burden, with more than one million deaths per year and increasing prevalence. 1 Fibrosis development is considered the final response to hepatic injury and inflammation due to viral infection, alcohol consumption, toxins, autoimmune diseases and other factors. 2 In advanced liver disease, hepatic inflammation is suspected to be additionally maintained by gut-derived pathogen-associated molecular patterns (PAMPs) that increasingly reach the liver due to a disrupted intestinal barrier and impaired immune responses. 3 In the liver, recognition of PAMPs by toll-like receptors of immune cells leads to the secretion of pro-inflammatory cytokines, 4 and subsequent hepatic as well as systemic inflammation.
Toll-like receptors are usually expressed by sentinel cells such as macrophages and dendritic cells. In the hepatic sinusoids, resident macrophages (Kupffer cells) constitute the first contact point for gutderived PAMPs like lipolpolysaccharide (LPS, endotoxin). Activation of Kupffer cells has recently been shown to play a crucial role in inflammation and fibrosis progression in different liver diseases. [5] [6] [7] Markers of macrophage activation sCD163 and soluble mannose receptor (sMR) are detectable in peripheral blood and correlate well with liver disease severity and portal hypertension. [8] [9] [10] [11] [12] [13] CD163, the haemoglobin-haptoglobin scavenger receptor, is expressed on macrophages and monocytes, 14 and is released into circulation as soluble (s)CD163 after shedding from immune cells. sCD163 levels are associated with prognosis in severe alcoholic hepatitis, 15 cirrhosis of different aetiologies 12, 16, 17 and acute or chronic liver failure. 9 In alcoholic hepatitis, sCD163 levels correlate well with markers of the LPS-pathway 15 supporting the hypothesis of gut-derived PAMPs as activators of liver macrophages. sMR, the shedding product of the mannose receptor located primarily on macrophages and dendritic cells, is not yet investigated as detailed as sCD163, but has been proven to be elevated in patients with liver disease and in patients with critical illness. 8, 18 The Child-Pugh and model for end-stage liver disease (MELD) scores represent the two most commonly used prognostic tools for patients suffering from liver cirrhosis. The Child-Pugh score was originally used to predict mortality in cirrhotic patients undergoing surgery 19 and is based on standard laboratory and clinical characteristics. The MELD score was introduced as a prognostic tool in advanced cirrhotic patients scheduled for TIPSS (transjugulary intrahepatic porto-systemic shunt) placement with advanced liver cirrhosis 20 and has shown its prognostic value especially in decompensated patients. However, these prognostic models are based on parameters that are predominantly manifestations of liver disease and do not take markers of disease pathogenesis or progression into account.
Therefore, our aim was to examine the predictive value of plasma levels of sCD163 and sMR (biomarkers of macrophage activation) and compare them to established models in a well-characterised cohort of predominantly compensated cirrhotics.
Furthermore, we correlated sCD163 and sMR with markers of gut permeability (diamine oxidase, lactulose-mannitol ratio), bacterial This study was part of an intervention study (NCT01607528). 
| Laboratory assays
Levels of sCD163 in plasma samples were measured by an in-house sandwich enzyme-linked immunosorbent assay (ELISA) using a BEP-2000 ELISA-analyser (Dade Behring) as previously described. 9, 23 Levels of sMR in plasma samples were measured by an in-house ELISA assay as previously described. France) was used as previously described. 21 The differential sugar absorption test was performed with lactulose (10 g) and mannitol
(5 g) and analysed by nuclear magnetic resonance spectroscopy as previously described. Table 1 .
3.2 | sCD163 and sMR levels correlate with liver disease severity
The median sCD163 and sMR levels were significantly higher in cirrhotic patients compared to healthy controls and gradually increased with disease severity (Figure 1 , Table S1 and We observed an association between sCD163 and sMR (q = 0.864, P < .001). Furthermore, both markers correlated in various strengths with markers of gut permeability and immune activation (Table 2) .
| sCD163 and sMR levels predict mortality
Patients with high sCD163 or high sMR levels had significantly worse survival. Survival curves for macrophage activation biomarkers and standard prognostic models are depicted in Figure 3 . According to Youden index, the optimal cut-off for survival prediction for sCD163 was 5.9 mg/L with a sensitivity of 76.2% and specificity of 65.0%, and for sMR 45.5 lg/dL with a sensitivity of 71.4% and a specificity of 65.0%. The cut-off value for MELD-score group classification was 13.6 (sensitivity 52.4%, specificity 80%). & DAO remained in the final model for survival prediction (Table 3) .
A variance inflation factor of 1.04 and tolerance of 0.96 showed no multicollinearity between the two variables. (Figure 4 ). This was also observed when analysing subsequent development of ascites, hepatic encephalopathy or jaundice separately (Table S5) . Markers of macrophage activation were not higher in patients developing infections requiring antibiotic therapy within 12 months (Table S5) . AUROCs for 1-year complication rate are depicted in Figure 5 .
| DISCUSSION
In this study, we investigated the prognostic value of macrophage activation markers sCD163 and sMR in a cohort of well- Liver macrophages represent >80% of the total macrophage population 26 and play a key role in the development and progression of liver inflammation and fibrosis. 5, 6 Elevated plasma concentrations of sCD163 and sMR reflect activation and proliferation of hepatic macrophages 11, 15 and correlate well with disease severity and portal hypertension in patients with liver disorders [9] [10] [11] [12] In our study, a gradual increase in both values was observed in cirrhotic patients that correlated with increasing Child-Pugh score. sCD163 and sMR levels were significantly higher in patients with ascites at baseline and gradually increased in relation to D'Amico's clinical stages of cirrhosis that mainly reflect severity of portal hypertension. 22 This supports the hypothesis of macrophage involvement in portal hypertension, probably via secretion of vasoactive substances and activation of stellate cells. 27 Progression of fibrosis and portal hypertension is inevitably associated with occurrence of complications of cirrhosis.
Hence, recent studies have proven sCD163 to be a predictor of disease progression 12 and variceal bleeding in cirrhosis. 16 Both parameters have additionally been shown to predict survival in cirrhotic patients in different studies. 9, 12, 16 The longest follow-up was reported in the study of Waidmann et al 16 who observed patients for 7 months in median. In our study, patients were prospectively observed for a median follow-up of 37 months. Both sCD163 and sMR showed similar prognostic value regarding long-term survival In a recent study, Laursen et al 28 assessed levels of sMR in patients scheduled for TIPSS implantation and found that sMR levels were elevated in all patients, but especially in patients with acute variceal bleeding indicating sMR as a marker for cirrhosis complications.
Actually, the mannose receptor is expressed not only on macrophages, but also on subsets of dendritic and especially endothelial cells 29 that might be activated in patients with portal hypertension.
Therefore, sMR might find its role as a slightly different biomarker compared to sCD163, possibly for prediction of complications and marker of portal hypertension.
In patients with liver cirrhosis, macrophages seem to be constitutively activated, since in our patients, levels of sCD163 and sMR were significantly higher in patients compared to healthy controls.
Activation is suspected to be maintained by gut-derived PAMPs like endotoxins 15, [30] [31] [32] that are especially detectable in portal blood of cirrhotic patients 33 and therefore, are suspected to enter the body via a disrupted gut barrier. 34 Our data emphasises this hypothesis, since shedding in response to inflammatory stimuli. [35] [36] [37] sCD14 can bind endotoxin and present it to cells which do not express the membrane bound form. 38 The correlations between sCD163/sMR and sCD14
were rather weak in our cohort although correlations have been found before. This might be due to the low serum concentrations of sCD14 that were comparable to healthy controls within this cohort, probably due to the inclusion of patients with stable disease. Since sCD14 can bind to endotoxin and then to a cell, increased endotoxin levels might lead to a decreased bioavailability of sCD14 in serum, making simple numeric correlation hard to interpret. However, experimental studies are needed to better define the causal relationship between gut barrier dysfunction and macrophage activation.
Our study has some limitations: Our study was performed as a single-centre study; however, we managed to recruit a relatively large number of patients with different aetiologies and observed them for a median follow-up of 37 months. Since overall mortality was low with only 21 deaths in our cohort, further analysis in terms of model development was not possible.
Taken together, the overexpression of macrophage activation markers, sCD163 and sMR, and its relation to gut barrier defects in cirrhotic patients reflect the detrimental impact of bacterial translocation on liver function. Both markers have shown predictive value regarding long-term survival. In addition, sMR was identified as a promising predictor of cirrhosis-associated complications. Our data also suggest macrophages as a possible therapeutic target to interrupt inflammation and fibrosis progression in patients with chronic liver disease.
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